Abstracts tagged "Outcome measures"

Abstract Number: 1723 • 2012 ACR/ARHP Annual Meeting
The Development of the Rheumatoid Arthritis Patient Priorities in Pharmacological Intervention Outcome Measures
Tessa Sanderson¹, John R. Kirwan², Marianne Morris¹, Jon Pollock³, Robert Noddings², Anne Watts² and Sarah Hewlett⁴, ¹University of the West of England, Bristol, United Kingdom, ²Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ³Faculty of Health and Life Sciences, University of the West of England, Bristol, United Kingdom, ⁴Academic Rheumatology, University of the West of England, Bristol, United Kingdom
Background/Purpose: Previous research developed a set of 8 priority treatment outcomes generated by patients to complement the professionally developed ACR core set for RA. These…
Abstract Number: 359 • 2012 ACR/ARHP Annual Meeting
Improved Radiological Outcome of Rheumatoid Arthritis: Early Treatment with methotrexate might be a key Prognostic Factor
Christoph Fiehn¹, Elisabeth Belke-Voss¹, Dietmar Krause², Siegfried Wassenberg³ and Rolf Rau⁴, ¹ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ²Dept. for Medical Informatics, Biometry and Epidemiology, Ruhr University, Bochum, Germany, ³Rheumaklinik, Evangelisches Fachkrankenhaus Ratingen, Rheumazentrum, Ratingen, Germany, ⁴Düsseldorf, Germany
Background/Purpose: To compare the rate of radiological progression in patients with rheumatoid arthritis (RA) diagnosed in the 1980s with those of the late 1990s until…
Abstract Number: 1578 • 2012 ACR/ARHP Annual Meeting
How Disease Activity Trajectories Affect the Willingness to Change Treatment
Paul Falzer¹ and Liana Fraenkel², ¹Medicine, VA Connecticut Healthcare System, New Haven, CT, ²Medicine, Section of Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT
Background/Purpose: Disease activity (DA) can change markedly over a short period, for a variety of reasons. The changes influence clinical practice and affect the willingness…
Abstract Number: 298 • 2012 ACR/ARHP Annual Meeting
Childhood-Onset Predicts Increased Disease Damage and Steroid Toxicity in a Cohort of Adults with Systemic Lupus Erythematosus
Erica F. Lawson¹, Laura Trupin², Jinoos Yazdany³, Aimee Hersh⁴, Emily von Scheven⁵ and Edward H. Yelin⁶, ¹Pediatrics, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Pediatrics, University of Utah, Salt Lake City, UT, ⁵Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, ⁶Arthritis Research Group, University of California, San Francisco, San Francisco, CA
Background/Purpose: While previous work has shown that adults with childhood-onset systemic lupus erythematosus (cSLE) have increased risk of mortality, renal disease and myocardial infarction as…
Abstract Number: 1526 • 2012 ACR/ARHP Annual Meeting
Patient Reported Outcomes in ANCA-Associated Vasculitis. A Prospective Comparison Between Birmingham Vasculitis Activity Score and Routine Assessment of Patient Index Data 3
Osama ElSallabi¹, Joel A. Block¹ and Antoine Sreih², ¹Section of Rheumatology, Rush University Medical Center, Chicago, IL, ²Medicine/Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: ANCA-associated vasculitis (AAV) is a rare group of diseases comprising Granulomatosis with polyangiitis (Wegener’s; GPA), Microscopic Polyangiitis (MPA), and Churg-Strauss Syndrome (CSS). These diseases…
Abstract Number: 307 • 2012 ACR/ARHP Annual Meeting
Risk Factors for Poor Outcomes in Hospitalized Patients with Pediatric Systemic Lupus Erythematosus
Mary Beth F. Son¹, Victor M. Johnson², Mindy S. Lo³ and Karen H. Costenbader⁴, ¹Division of Rheumatology and Immunology, University Children's Medical Institute, Singapore, Singapore, ²Department of Anesthesiology, Perioperative and Pain Medicine, Children's Hospital Boston, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Boston, MA, ⁴Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Disparities in care among adults with SLE are well documented. We investigated associations of demographic factors and volume of annual inpatient hospital admissions with…
Abstract Number: 1468 • 2012 ACR/ARHP Annual Meeting
Patient Perspective Informs Core Sets, Constructs of Metrics and Communication Tools for Patients with Connective Tissue Disease Related Interstitial Lung Disease
Shikha Mittoo¹, Sid Frankel², Daphne LeSage³, Flavia V. Castelino⁴, Lisa Christopher-Stine⁵, Sonye Danoff⁶, Aryeh Fischer⁷, Laura K. Hummers⁸, Ami A. Shah⁸, Jeffery J. Swigris⁹, Sophia Cenac¹⁰, Sancia Ferguson¹¹, Ignacio Garcia-Valladares¹², Maithy Tran¹³, Harmanjot K. Grewal¹⁴ and Lesley Ann Saketkoo¹⁵, ¹Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ²University of Manitoba, Winnipeg, Canada, ³Center for CCH at State of Louisiana, New Orleans, LA, ⁴Rheumatology, Massachusetts General Hospital, Boston, MA, ⁵Medicine and Neurology, Johns Hopkins University, Baltimore, MD, ⁶Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, ⁷Rheumatology / ILD Program, National Jewish Health, Denver, CO, ⁸Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Autoimmune Lung Center, National Jewish Health, Denver, CO, ¹⁰Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University Health Science Center, New Orleans, LA, ¹¹Tulane University School of Medicine, ¹²Rheumatology, Guadalajara, Guadalajara, Mexico, ¹³Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁴Rheumatology, Lousiana State University Health Sciences Center, New Orleans, LA, ¹⁵LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA
Background/Purpose: Limited information on the patient experience exists in CTD-ILD. Herein supports that the patients' perspective is essential to informing clinical practice and in…
Abstract Number: 90 • 2012 ACR/ARHP Annual Meeting
Physical Function, Pain and Fatigue Are Related to Sleep Disturbance in Females with Rheumatoid Arthritis
Cathrine Austad¹, Tore K. Kvien² and Till Uhlig², ¹Department of Rheumatology, Diakonhjemmet Hospital, Norway, Oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Sleep quality is an important aspect of health and well-being and the Outcome Measures in Rheumatology Clinical Trials group has identified sleep quality as…
Abstract Number: 1473 • 2012 ACR/ARHP Annual Meeting
Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis
Giuseppina Abignano¹, Giovanna Cuomo², Maya H. Buch³, William M. Rosenberg⁴, Gabriele Valentini⁵, Paul Emery⁶ and Francesco Del Galdo⁷, ¹Chapel Allerton Hospital Leeds Insitute of Molecular medicine, Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Department of Internal and Experimental Medicine, Second University of Naples, Naples, Italy, ³Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ⁴Centre for Hepatology - UCL, London, United Kingdom, ⁵Rheumatology/Int Med, Second University of Naples, Rheumatology Unit, Naples, Italy, ⁶Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and NIHR LMBRU, Leeds, United Kingdom, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: A recent large multicenter study has identified an algorithm, known as Enhanced Liver Fibrosis (ELF), by combining the serum concentrations of amino-terminal propeptide of procollagen type III (PIIINP),…
Abstract Number: 1307 • 2012 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless “First-in-Human” Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment
Steven De Bruyn¹, Béla Gachályi², Bernadette Rojkovich³, Slavomir Bruk⁴, Petr Sramek⁵, Mariusz Korkosz⁶, Krzysztof Krause⁷, Pieter Schoen⁸, Laura Sargentini-Maier⁹, Joke D'Artois¹⁰, Katrien Verschueren¹⁰, Katelijne De Swert¹⁰, Gerhard Arold¹¹ and Josefin-Beate Holz¹², ¹Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, ²Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Péterfy Sándor Utcai Kórház, Budapest, Hungary, ³II. sz. Reumatológiai Osztály, Budai Irgalmasrendi Kórház Kht., Budapest, Hungary, ⁴Interni oddeleni, Nemocnice Trinec, Trinec, Czech Republic, ⁵Pharmaceutical Research Associates CZ, Praha, Czech Republic, ⁶Malopolskie Centrum Medyczne, Krakow, Poland, ⁷Specjalistyczny im. J. Gromkowskiego, Wojewodzki Szpital, Wroclaw, Poland, ⁸Project Management, Ablynx N.V., Zwijnaarde, Belgium, ⁹Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ¹⁰Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ¹¹Medical Affairs, PRA International GmbH, Berlin, Germany, ¹²Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: ALX-0061 is a 26kD bispecific IL-6R targeting Nanobody® with monovalent binding to IL-6R and serum albumin. It effectively neutralizes IL-6 pathway activity in-vitro and…
Abstract Number: 1283 • 2012 ACR/ARHP Annual Meeting
Effects of Tofacitinib On Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Receiving Stable-Dose Methotrexate: Results of Two Phase 3 Studies
Gerd Burmester¹, Désirée van der Heijde², Vibeke Strand³, Cristiano A. F. Zerbini⁴, Carol A. Connell⁵, Charles A. Mebus⁵, Samuel H. Zwillich⁶, John D. Bradley⁵, David Gruben⁵ and Gene Wallenstein⁵, ¹Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁴Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. The efficacy and safety of…
Abstract Number: 1155 • 2012 ACR/ARHP Annual Meeting
A New Measure of Visual Function for Children with Juvenile Idiopathic Arthritis-Associated Uveitis
Sheila T. Angeles-Han¹, Steven Yeh², Courtney McCracken¹, Larry B. Vogler³, Kelly A. Rouster-Stevens⁴, Christine W. Kennedy⁵, Kirsten Jenkins⁶, Matthew Kent³, Scott Lambert⁷, Carolyn Drews-Botsch⁸ and Sampath Prahalad⁹, ¹Emory University School of Medicine, Atlanta, GA, ²Ophthalmology, Emory University School of Medicine, Atlanta, GA, ³Dept of Pediatrics, Emory Univ School of Medicine, Atlanta, GA, ⁴Pediatric Rheumatology, Emory Univ School of Medicine, Atlanta, GA, ⁵Rheumatology Immunology, Emory Children's Center, Atlanta, GA, ⁶Children's Healthcare of Atlanta, Atlanta, GA, ⁷Ophthalmology, Emory Univ School of Medicine, Atlanta, GA, ⁸Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁹Pediatrics, Emory Children's Center, Atlanta, GA
Background/Purpose: Studies on outcomes of children with juvenile idiopathic arthritis-associated uveitis (JIA-U) focus on the clinical ocular exam and physical disability secondary to arthritis. This…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.